All In Biotech

Drug Trial Radar · NCT01560286

A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

A Phase II, Multi-center, Open-label, Dose-finding Study to Evaluate Safety, Efficacy and Tolerability of Subcutaneously (SC) Administered rAvPAL-PEG in Patients With PKU for 24 Weeks

Last checked: Nov 20, 2026Latest source record: Aug 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

May 2012

Primary completion

Sep 2013

Study completion Jul 2015

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Mar 22, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the effect of dosing regimens of multiple subcutaneous (SC) doses of rAvPAL-PEG to induce an early and sustained Phe reduction while decreasing the frequency and severity of hypersensitivity reactions in patients with PKU.

Conditions

  • Phenylketonuria

Interventions

  • BMN 165 (rAvPAL-PEG)Biological

    Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood Phenylalanine ConcentrationTime frame: Baseline, Week 24

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The Children's Hospital

    Aurora, Colorado

  • University of Florida, Gainesville

    Gainesville, Florida

  • Children's Hospital Boston

    Boston, Massachusetts

  • Nebraska Medical Center

    Omaha, Nebraska

  • Albany Medical Center

    Albany, New York

  • University of Utah Hospital

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.